What is I-Mab (IMAB) Stock Return on Shareholders’ Capital?

I-Mab (NASDAQ: IMAB) stock jumped 1.09% on Wednesday to $3.70 against a previous-day closing price of $3.66. With 0.16 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.54 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.7600 whereas the lowest price it dropped to was $3.6015. The 52-week range on IMAB shows that it touched its highest point at $67.84 and its lowest point at $3.25 during that stretch. It currently has a 1-year price target of $40.02.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IMAB was down-trending over the past week, with a drop of -14.94%, but this was down by -1.86% over a month. Three-month performance dropped to -37.82% while six-month performance fell -65.19%. The stock lost -94.25% in the past year, while it has lost -92.19% so far this year. A look at the trailing 12-month EPS for IMAB yields -4.02 with Next year EPS estimates of -1.47.

Float and Shares Shorts:

At present, 82.11 million IMAB shares are outstanding with a float of 81.65 million shares on hand for trading. On Oct 13, 2022, short shares totaled 2.2 million, which was 2.64% higher than short shares on Sep 14, 2022. In addition to Dr. Jingwu Zhang Zang M.D., Ph.D. as the firm’s Founder & Chairman, Dr. Andrew X. Zhu M.D., Ph.D. serves as its Member of Scientific Advisory Board, Pres, Acting CEO & Director.

Institutional Ownership:

Through their ownership of 60.51% of IMAB’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 33.14% of IMAB, in contrast to 11.08% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in IMAB with 8.69% of the stake, HHLR Advisors Ltd. holds 7,182,850 shares worth 7,182,850. A second-largest stockholder of IMAB, GIC Pte Ltd., holds 4,709,783 shares, controlling over 5.70% of the firm’s shares. Nomura Securities Co., Ltd. is the third largest shareholder in IMAB, holding 2,613,214 shares or 3.16% stake. With a 1.29% stake in IMAB, the Government Pension Fund – Global is the largest stakeholder. A total of 1,069,544 shares are owned by the mutual fund manager. The Artisan International Small-Mid F, which owns about 0.96% of IMAB stock, is the second-largest Mutual Fund holder. It holds 793,859 shares valued at 2.95 million. Vanguard Emerging Markets Stock I holds 0.91% of the stake in IMAB, owning 754,085 shares worth 2.8 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IMAB since 12 analysts follow the stock currently. There are 11 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With IMAB analysts setting a high price target of $64.60 and a low target of $3.80, the average target price over the next 12 months is $32.77. Based on these targets, IMAB could surge 1645.95% to reach the target high and rise by 2.7% to reach the target low. Reaching the average price target will result in a growth of 785.68% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. IMAB will report FY 2022 earnings on 03/28/2023. Analysts have provided yearly estimates in a range of -$1.34 being high and -$3.03 being low. For IMAB, this leads to a yearly average estimate of -$2.14. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. I-Mab surprised analysts by $0.25 when it reported -$0.99 EPS against a consensus estimate of -$1.24. The surprise factor in the prior quarter was $0.23. The average estimate for the next quarter is thus -$0.23.

Leave a Comment

Your email address will not be published. Required fields are marked *




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam